P M J Welsing, J L Severens, R F J M Laan. Show Affiliations »
Abstract
Mesh: See more » Antibodies, Monoclonal/economicsAntirheumatic Agents/economicsArthritis, Rheumatoid/drug therapyCost-Benefit AnalysisHumansInfliximabModels, EconometricResearch Design
Substances: See more » Antibodies, MonoclonalAntirheumatic AgentsInfliximab
Year: 2003 PMID: 14645870 DOI: 10.1093/rheumatology/keg456
Source DB: PubMed Journal: Rheumatology (Oxford) ISSN: 1462-0324 Impact factor: 7.580